London, UK; Brentwood, TN, US: 25 September 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that, on 24 September 2007, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from Aviva plc. The notification follows an increase in the combined direct and indirect voting rights of Aviva plc and its subsidiaries to 12.05% of total voting rights. Further details are as follows:
